Education, Science, Technology, Innovation and Life
Open Access
Sign In

Effect of Icaritin on non-small cell lung cancer NCI-H1299 cells

Download as PDF

DOI: 10.23977/tranc.2024.050108 | Downloads: 6 | Views: 160


Lixia Hou 1,2, Xinru Feng 1,2, Bo Xiao 1,2, Dong Yao 3,4


1 Key Laboratory of Respiratory Diseases, Affiliated Hospital of Guilin Medical University, Guilin, 541004, China
2 Key Laboratory of Basic Research on Respiratory Diseases, Guangxi Health Commission, Affiliated Hospital of Guilin Medical University, Guilin, 541004, China
3 Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China
4 Guangxi Clinical Research Center for Diabetes and Metabolic Diseases, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China; Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Key Laboratory of Respiratory Diseases, Education Department of Guangxi Zhuang Autonomous Region, Guilin Medical University, Guilin, 541000, China

Corresponding Author

Dong Yao


Chinese herbal medicine has indeed been used for centuries in China as a treatment for various ailments, including lung cancer. The use of Chinese herbal medicine in cancer treatment is often based on traditional Chinese medicine (TCM) principles, which emphasize restoring balance and harmony within the body. Icaritin is a natural compound extracted from plants of the Epimedium genus, the anticancer activity of which has been extensively studied. However, the anti-tumor effect of icaritin on the non-small cell lung cancer cell line NCI-H1299, which lacks the P53 gene, has not been reported. In this study, we evaluated the anticancer effect of icaritin on NCI-H1299 cells by treating these cells with different concentrations of icaritin. We find that icaritin significantly induces apoptosis and autophagy and inhibits proliferation and migration, icaritin induced autophagy in H1299 cells. These results indicate that icaritin is a potential therapeutic drug for patients with lung cancer with P53 gene deletion.


Icaritin, Tumor Suppressor Protein p53, Anticancer, NCI-H1299 cells, Autophagy


Lixia Hou, Xinru Feng, Bo Xiao, Dong Yao, Effect of Icaritin on non-small cell lung cancer NCI-H1299 cells. Transactions on Cancer (2024) Vol. 5: 53-62. DOI:


[1] AMANDA L, RAJWANTH R V, JUAN P W. The global burden of lung cancer: current status and future trends.[J]. Nat Rev Clin Oncol. 2023;20(9): 624-639.
[2] BOGART J A, WAQAR S N, MIX M D. Radiation and systemic therapy for limited-stage small-cell lung cancer[J]. Journal of Clinical Oncology. 2022;40(6): 661.
[3] X L, B X, T Z, X Z, Y Z. Down-regulation of microRNA-10a mediates the anti-tumor effect of icaritin in A549 cells via the PTEN/AKT and ERK pathway.[J]. General physiology and biophysics. 2019;38(6): 525-533.
[4] C Y, YY J, J M, et al. Identification of icaritin derivative IC2 as an SCD-1 inhibitor with anti-breast cancer properties through induction of cell apoptosis.[J]. Cancer cell international. 2022;22(1): 202.
[5] HU J, WU X, YANG C, et al. Anticancer effect of icaritin on prostate cancer via regulating miR‐381‐3p and its target gene UBE2C[J]. Cancer Medicine. 2019;8(18): 7833-7845.
[6] YU Z, GUO J, HU M, GAO Y, HUANG L. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma[J]. Acs Nano. 2020;14(4): 4816-4828.
[7] LI Q, HUAI L, ZHANG C, et al. Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways[J]. International journal of hematology. 2013;97(5): 617-623.
[8] LI H, LIU Y, JIANG W, et al. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma[J]. BMC cancer. 2021;21: 1-12.
[9] JIN L, MIAO J, LIU Y, et al. Icaritin induces mitochondrial apoptosis by up-regulating miR-124 in human oral squamous cell carcinoma cells[J]. Biomedicine & Pharmacotherapy. 2017;85: 287-295.
[10] LIU M, HU T, GOU W, et al. Exploring the pharmacological mechanisms of icaritin against nasopharyngeal  carcinoma via network pharmacology and experimental validation[J]. Front Pharmacol. 2022;13: 993022.
[11] MAN S, LUO C, YAN M, ZHAO G, MA L, GAO W. Treatment for liver cancer: From sorafenib to natural products[J]. European journal of medicinal chemistry. 2021;224: 113690.
[12] LI S, PRICEMAN S J, XIN H, et al. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma[J]. PLoS One. 2013;8(12): e81657.
[13] YANG X J, XI Y M, LI Z J. Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy[J]. Biomed Res Int. 2019;2019: 4860268.
[14] XU B, JIANG C, HAN H, et al. Icaritin inhibits the invasion and epithelial‐to‐mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/AKt/HIF‐1α signalling[J]. Clinical and Experimental Pharmacology and Physiology. 2015;42(12): 1296-1307.
[15] ZHOU X, WU D, MI T, LI R, GUO T, LI W. Icaritin activates p53 and inhibits aerobic glycolysis in liver cancer cells[J]. Chemico-Biological Interactions. 2024;392: 110926.
[16] PULESTON D J, SIMON A K. Autophagy in the immune system[J]. Immunology. 2014;141(1): 1-8.
[17] LEE Y J, WON A J, LEE J, et al. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells[J]. International journal of medical sciences. 2012;9(10): 881.
[18] LI Y, LEI Y, YAO N, et al. Autophagy and multidrug resistance in cancer[J]. Chinese journal of cancer. 2017; 36: 1-10. 

Downloads: 533
Visits: 33285

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.